Efficacy of using oral methotrexate with phototherapy in the treatment of vitiligo in comparison with single phototherapy treatment: A double‐blinded randomized controlled trial
Photodermatology, Photoimmunology & Photomedicine · 2023
DOI: 10.1111/phpp.12918 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Photodermatology, Photoimmunology & Photomedicine, 2023. Verfasst von Vahide Lajevardi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, RAZI Hospital, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Vitiligo, Ultraviolet Therapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Tehran University of Medical Sciences and Health Services.
Abstract (Originalsprache)
Background
Vitiligo is an acquired skin disease with a worldwide prevalence of 0.5%–2% and a tendency to involve both genders. Although the exact pathologic mechanism is unknown, there is some evidence for the role of autoimmunity in this disease. Based on this theory, various immunosuppressive agents, such as topical or systemic corticosteroids and phototherapy (including narrowband ultraviolet B), are used. Methotrexate is another immunosuppressant that has recently become popular as a single treatment for vitiligo; however, the synergistic effect and its superiority over other treatments are two crucial factors that are still obscure. This study aimed to compare the efficacy of methotrexate+ NB‐UVB versus placebo+ NB‐UVB in vitiligo patients.
Methods
In this double‐blinded, randomized controlled trial, 42 patients were randomly allocated into two groups: the first group received three times weekly NB‐UVB plus placebo, and the second group was treated with three times weekly NB‐UVB in combination with a weekly dose of 12.5 mg MTX. The total duration of treatment was 6 months, patients were followed up every 2 months, and the assessment tools were VASI (repigmentation indicator) and VIDA (disease activity indicator) scores.
Results
Both treatment groups showed improvement in VASI and VIDA scores during 6‐month follow‐up, but no statistical significance was found between the two treatment methods.
Conclusion
This study demonstrated that both treatment modalities were equally effective, and further studies are required to evaluate the efficacy of MTX with other medications with longer follow‐up and a larger sample size.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, RAZI Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Förderung
- Tehran University of Medical Sciences and Health Services
Zitieren
APA
Lajevardi, V., Hosseini, Z. S. S., & Heidari, S. (2023). Efficacy of using oral methotrexate with phototherapy in the treatment of vitiligo in comparison with single phototherapy treatment: A double‐blinded randomized controlled trial. Photodermatology, Photoimmunology & Photomedicine. https://doi.org/10.1111/phpp.12918
Vancouver
Lajevardi V, Hosseini ZSS, Heidari S. Efficacy of using oral methotrexate with phototherapy in the treatment of vitiligo in comparison with single phototherapy treatment: A double‐blinded randomized controlled trial. Photodermatology, Photoimmunology & Photomedicine. 2023. doi:10.1111/phpp.12918
BibTeX
@article{Lajevardi2023,
author = {Lajevardi, Vahide and Hosseini, Zahra Sadat Seyed and Heidari, Sama},
title = {Efficacy of using oral methotrexate with phototherapy in the treatment of vitiligo in comparison with single phototherapy treatment: A double‐blinded randomized controlled trial},
journal = {Photodermatology, Photoimmunology & Photomedicine},
year = {2023},
doi = {10.1111/phpp.12918}
}
EUVIMED